


**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup>:</b><br><b>A61K 31/41 // C07D 271/12</b>  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/61018</b><br><b>(43) International Publication Date:</b> 2 December 1999 (02.12.99)   |
| <b>(21) International Application Number:</b> PCT/IB99/00893<br><b>(22) International Filing Date:</b> 17 May 1999 (17.05.99)<br><br><b>(30) Priority Data:</b><br>935/CAL/98      22 May 1998 (22.05.98)      IN<br><br><b>(71)(72) Applicant and Inventor:</b> SANKARANARAYANAN,<br>Alangudi [IN/IN]; B-7, Swastik Park, Premchandnagar<br>Road, Bodakdev, Ahmedabad - 380054, Gujarat State (IN).<br><br><b>(74) Agents:</b> AHUJA, Sudhir, D. et al.; D.P. Ahuja & Co., 53, Syed<br>Amir Ali Avenue, Calcutta - 700019, West Bengal (IN).  |           | <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG,<br>BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB,<br>GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,<br>KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,<br>MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,<br>SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA,<br>ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ,<br>UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,<br>RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK,<br>ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI<br>patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR,<br>NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> USE OF BENZOFUROXAN DERIVATIVES IN TREATING ANGINA PECTORIS<br><br><div style="text-align: center;"><span style="float: right;">(I)</span></div><br><b>(57) Abstract</b><br><p>The invention discloses use of a compound of the benzofuroxan series for treatment of cardiovascular disorders represented by general formula (I) and pharmaceutically acceptable salts thereof, wherein R is halogen, acetoxy, -X-R', -C(O)NR''R''', or -C(O)Cl, wherein X is oxygen sulfur, -C(O)-, or -C(O)O-; R' is hydrogen, straight chain or branched lower alkyl (C<sub>1</sub>-C<sub>8</sub>); R'' and R''' is independently hydrogen, straight chain or branched lower alkyl (C<sub>1</sub>-C<sub>8</sub>) or R'' and R''' are linked together with or without heteroatom such as oxygen or nitrogen wherein substitution on nitrogen is hydrogen or lower alkyl. The invention further discloses pharmaceutical compositions containing compounds of general formula (I) as active ingredients. The invention also discloses a method of treatment of mammal, including man, of coronary heart disease by administration of an effective amount of a compound of formula (I) as defined above.</p> |           |  |

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

## USE OF BENZOFUROXAN DERIVATIVES IN TREATING ANGINA PECTORIS

**FIELD OF THE INVENTION**

5        This invention relates to the use of the compounds of benzofuroxan series in therapeutics. In particular the invention concerns pharmaceutical compositions containing benzofuroxan derivatives as active ingredients and their use as tolerance resistant nitric oxide donors in treatment of angina pectoris.

**BACKGROUND OF THE INVENTION**

10       After the discovery of endothelium-derived relaxing factor (EDRF) by Furchgott et al (1980), and the elucidation of the biochemistry of EDRF by a number of laboratories (Ignarro, 1989; Vane et al, 1990; Bassenge et al, 1988; and Vanhoutte, 1989), it is now widely accepted that EDRF is the endogenous nitrovasodilator, nitric oxide (NO) donor. The organic nitrates and related compounds owe their  
15       pharmacological action to the release of nitric oxide (NO) and these compounds are collectively called nitrovasodilators. NO stimulates the guanylate cyclase enzyme in vascular smooth muscle cells resulting in increased levels of cyclic GMP. This leads to dephosphorylation of myosin light chain which results in relaxation of smooth muscles (Murad, 1986). NO is known to be involved in a number of bio-regulatory processes  
20       like, vasodilatation, platelet deaggregation, vascular smooth muscle proliferation, etc.

      Organic nitrates are used in prophylaxis, treatment and management of patients with angina pectoris. These are also useful in congestive heart failure associated with acute myocardial infarction, hypertension associated with surgical procedures and to produce controlled hypotension during surgical procedures. Among organic nitrates,  
25       nitroglycerine (sublingual) which is currently in use, is the drug of choice for

immediate relief of anginal symptoms. Prophylactic treatment of stable angina pectoris involves the use of one or more drugs such as long acting nitrates like isosorbide dinitrate, a beta-blocker and/or a calcium channel antagonist, particularly in patients  
5 likely to experience coronary spasm. In some cases this triple therapy satisfactorily control angina. They are quite effective in the treatment of these conditions when used intermittently.

Frequently repeated use of nitrates result in decrease in their pharmacological effects, a phenomenon well recognized as nitrate tolerance. The mechanism of  
10 tolerance is not well defined. As early as 1973, Needleman and Johnson (1973) have reported that tolerance to nitroglycerine could occur in isolated rabbit arteries. It was hypothesized by them that depletion of sulphydryl groups was associated with the development of tolerance to nitroglycerine. This is a major problem in the clinical use of organic nitrates (Frampton et al, 1992). Currently, the development of tolerance is  
15 reduced by the use of intermittent dosing schedule with a nitrate-free interval of 10 - 12 hrs. However, this intermittent use is associated with decreased exercise tolerance during the last part of nitrate-free interval. This suggests possibility of increased frequency of or severity of angina during nitrate-free interval. The importance of development of tolerance has increased as these drugs are used more commonly in  
20 various dosage forms like oral, transdermal, and intravenous preparations and even as sustained-release preparations. Several indirect indices like exercise duration, systemic blood pressure, pulmonary artery pressures and pulmonary artery wedge pressure has been used to assess tolerance to organic nitrates. However, it is not clear whether decreased response to nitrates is due to tolerance of the vascular smooth

muscle cells or changes in regulatory factors like activation of neurohumoral factors or fluid retention etc. (Armstrong and Moffat, 1983). Irrespective of the mechanisms of tolerance development, clinically it is important to develop nitric oxide donors with least tendency to develop tolerance.

- 5 P B Ghosh et al. (Journal of Medicinal Chemistry, 1968) disclosed the method of synthesis of various benzo -2,1,3- oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans) and their potential as antileukemic and immuno-suppressive drugs in vitro.

- 10 P B Ghosh et al. (Journal of Medicinal Chemistry, 1972) tested 4- nitro benzofurazans and 4- nitrobenzofuroxans bearing electron withdrawing substituents in the 5 and 6 position (relative to NO<sub>2</sub>) as potential antileukemic and immuno suppressive drugs in vitro.

- 15 Nishikawa et al. (The Journal of Pharmacology and Experimental Therapeutics, 1982) disclosed effect of N- ethoxycarbonyl -3- morpholinosydnonimine and its metabolites 3- morpholinosydnonimine, cyanomethyleneamino morpholine, N- nitroso -N- morpholinoamino acetonitrile as novel antianginal agents.

F. Murad (J. Clin. Invest, 1986) disclosed cyclic guanosine monophosphate as a mediator of vasodilation.

- 20 James Frampton et al. (Drug Evaluation, Adis International Limited, 1992) gives a review of pharmacology and therapeutic efficiency of nicorandil in angina pectoris. Nicorandil, which has both vasodilator and venodilating properties was found to offer an effective alternative to established vasodilator therapy with conventional nitrates and calcium antagonists in the long term treatment of stable angina pectoris.

US Patent No.5,272,164 disclosed novel carboximidamide derivatives particularly N-cyano-N<sup>1</sup>-substituted pyridine carboximidamide derivatives having vasodilating effect and hypotensive effect besides other physiological effects which are helpful in treatment of ischemic heart diseases.

5 US Patent 5,424,326 disclosed phenyl -1,2,5- oxadiazole carboxamide -2- oxide and its derivatives, which are useful for the treatment of disorders of the cardiovascular system.

F Benedini et. al. (J. Med. Chem. 1995) disclosed a new nitro ester -3- [(nitroxy) alkyl] -2H- 1,3- benzoxazin- 4(3H)- ones showing marked inhibitory activity against  
10 ischemia-induced electrocardiographic changes, with only limited systemic hemodynamic effects. These new nitro ester derivatives, endowed with marked anti-anginal activity, which is not associated with concurrent and pronounced fall in systemic blood pressure, are indicative of a new class of selective nitrovasodilators having a preferential action on large coronary vessels, which could be clinically  
15 relevant in the treatment of coronary artery diseases.

However, none of the above prior art disclosures on the drugs specifically used as vasodilator for treatment of cardiac ailments tackles the problem associated with the conventional NO-donors to develop tolerance in the patient after continuous use for a period of time. The present invention evaluates the benzofuroxan derivatives for their  
20 NO donor activities particularly with reference to their tendency to develop tolerance for continued application of the drug. Significantly, the invention identifies the molecules showing vasodilator activity without tendency to develop tolerance unlike the conventional nitric-oxide donors.

### SUMMARY OF THE INVENTION

The present invention provides, in the first aspect, benzofuroxan derivatives and pharmaceutically acceptable salts thereof, for their use in cardiovascular disorders like coronary heart diseases.

- 5      Such salts include, but are not limited to, oxalate, tartarate, maleate, methyl sulphonate, p-toluene sulphonate, etc.

The invention further provides pharmaceutical formulations comprising benzofuroxan derivatives to be used for treatment of cardiac disorders.

- The invention also provides for a method of treatment of mammals including human  
10    being of coronary heart diseases by administration of a compound of benzofuroxan series.


### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 gives the dose response curve for one of the test compound (compound No.8) and GTN.

- 15    Fig. 2 gives the dose response curves (percentage relaxation vs the log(M) concentration) for GTN and one of the test compounds (Compound No. 8) before and after development of tolerance.

### DETAILED DESCRIPTION OF THE INVENTION

- The compounds of the benzofuroxan series used for cardiovascular disorders are  
20    represented by the general formula (I).



and pharmaceutically acceptable salts thereof

wherein :

R is halogen, acetoxy,  $-X-R'$ ,  $-C(O)NR''R'''$  or  $-C(O)Cl$ ,

wherein X is oxygen, sulfur,  $-C(O)-$  or  $-C(O)O-$

5  $R'$  is hydrogen, straight chain or branched lower alkyl ( $C_1 - C_8$ )

$R''$  and  $R'''$  is independently hydrogen, straight chain or branched lower alkyl

( $C_1 - C_8$ ) or  $R''$  and  $R'''$  are linked together with or without heteroatom such

as oxygen or nitrogen wherein substitution on nitrogen is hydrogen or lower

alkyl.



10 The representative compounds of the invention showing tolerance resistant NO

donor activities as defined above are given in the Table - 1.

**TABLE - 1**

| Compound No. | R   |
|--------------|---|
| 1            | -Cl   |
| 2            | -S-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>    |
| 3            | -COOH   |
| 4            | -SCH <sub>3</sub>                                     |
| 5            | -OC(O)-CH <sub>3</sub>                                |
| 6            | -COCI   |
| 7            | -CHO  |
| 8            | -COOCH <sub>3</sub>                                   |
| 9            | -OH.HCl   |
| 10           | -CONH <sub>2</sub>                                    |
| 11           | -COOC <sub>2</sub> H <sub>5</sub>                     |
| 12           | -COOCH <sub>2</sub> -CH <sub>2</sub> -CH <sub>3</sub> |
| 13           | -COOCH(CH <sub>3</sub> ) <sub>2</sub>                 |
| 14           | -COO <sup>t</sup> Bu                                  |
| 15           | -CON(CH <sub>3</sub> ) <sub>2</sub>                   |
| 16           | substitution (a)                                      |
| 17           | substitution (b)                                      |
| 18           | -CONHCH(CH <sub>3</sub> ) <sub>2</sub>                |
| 19           | -CONH <sup>t</sup> Bu                                 |





The alkoxy carbonyl benzofuroxan derivatives of the general formula (I), and their pharmaceutically acceptable salts can be prepared by a process which comprises,

- 5 (a) reacting chlorocarbonyl benzofuroxan and an alcohol in solvent such as tetrahydrofuran at room temperature;
- (b) adding a base such as triethylamine to the reaction mixture;
- (c) refluxing the reaction mixture till the completion of the reaction;
- (d) removal of the solvent followed by addition of water and extraction
- 10 with organic solvent such as ethyl acetate;
- (e) concentration of ethyl acetate layer;
- (f) purification by column chromatography; and
- (g) optionally transforming into the corresponding pharmacologically acceptable salts.
- 15 Said products of steps (f) and (g) are characterized by m.p. and the conventional spectroscopic techniques.

The alkoxy carbonyl benzofuroxan derivatives of the general formula (I), and their pharmaceutically acceptable salts can also be prepared by a process which comprises,

- (a) reacting carboxy benzofuroxan with saturated solution of alcoholic HCl;
- (b) removal of excess of alcohol under reduced pressure to get the residue;
- (c) washing the residue with 0.2 N aq. NaOH solution, extracting with solvent such as ether and concentration of the ether layer,
- 5 (d) purification by column chromatography, and
- (e) optionally transforming into the corresponding pharmacologically acceptable salts.

Said products of steps (d) and (e) are characterized by m.p. and the conventional spectroscopic techniques.

- 10 The 5(6)-alkyl mercapto benzofuroxan derivatives of the general formula I, and their pharmaceutically acceptable salts can be prepared by a process which comprises,

- (a) reacting 2-nitro-4-alkylmercapto aniline with concentrated hydrochloric acid and sodium nitrite,
- (b) reacting the reaction product of step (a) with sodium azide to obtain 2-nitro  
15 -4-alkylmercapto phenyl azide,
- (c) thermal cyclization of 2-nitro-4-alkylmercapto phenyl azide in a solvent, such as toluene, benzene, or xylene to produce 5(6)-alkylmercapto benzofuroxan,
- (d) purification by column chromatography, and
- 20 (e) optionally transforming into the corresponding pharmacologically acceptable salts.

Said products of steps (d) and (e) are characterized by m.p. and the conventional spectroscopic techniques.

The alkoxy carbonyl benzofuroxan derivatives of general formula I can be further prepared by a process which comprises,

- (a) reacting carboxy benzofuroxan and an equimolar amount of an alcohol such as methanol, ethanol, isopropanol, tertiary butanol, etc. in methylene chloride,
- (b) adding 4-dimethylamino pyridine and N,N'-dicyclohexyl carbodiimide under stirring and continuing the stirring for a period of 2 to 16 hours at room temperature, to complete the reaction,
- (c) filtering the reaction mixture when the filtrate on evaporation under reduced pressure gives the crude product,
- (d) the product thus obtained is purified by column chromatography, and
- (e) optionally transforming into the corresponding pharmacologically acceptable salts.

Said products of steps (d) and (e) are characterised by m.p. and the conventional spectroscopic techniques.

#### **Pharmaceutical compositions for NO-donor molecules:**

The compounds according to this invention as given by general formula (I) or their salts or complexes can be administered orally, intravenously or parenterally as a pharmaceutical preparation in liquid or solid form. It may also be administered via topical, transdermal, sublingual, buccal or rectal route for example as a suppository, ointment, cream, powder, transdermal patch, metered aerosol or spray.

The pharmaceutically acceptable carriers present in the composition of this invention are materials recommended for the purpose of administering the medicament. These

may be liquid or solid materials, which are otherwise inert or medically acceptable and are compatible with the active ingredients.

### **EVALUATION OF THE BIOLOGICAL ACTIVITY:**

#### **Methods:**

##### **5 a) In vitro Screening of NO Donors**

The method adopted was a modified method of Nishikawa et al (1982). Albino rabbits of either sex were stunned and exsanguinated. Thoracic aorta was quickly removed and cut helically (at an angle of 45°) into strips 4-5 mm wide and 25 to 30 mm long, after removal of adventitial connective tissue. The endothelium was rubbed  
10 off gently using a cotton swab soaked in Kreb's solution. Two strips were fixed vertically in organ baths containing 20 ml. Kreb's solution maintained at 37°C and bubbled with oxygen. A resting tension of 4 g was applied and the preparation was allowed to equilibrate for 30min. Each preparation was exposed to two primer doses of KCl (30mM). After the contraction reached a maximum, the bath was drained off  
15 and replaced with fresh Kreb's solution. Half an hour later, cumulative dose response curve for the test compound was taken on one tissue (test) and for glyceryl trinitrate (GTN) in the other (standard). The dose range used was from  $10^{-9}$  M to  $10^{-3}$  M with a contact period of 4 min. for each dose. After the maximum relaxation was achieved with the last dose, papaverine ( $10^{-4}$  M) was added to obtain the maximum relaxation.

20 Tolerance was induced in both the tissues by adding 440  $\mu$ M of GTN for 90 minutes. During this period the bath solution was changed every 30 min. and 440  $\mu$ M of GTN was replaced. Later both the tissues were washed thoroughly and the dose response curve (DRC) for both the test compound and the standard were repeated. The percentage relaxation with individual doses was calculated by taking the

maximum relaxations to  $10^{-4}$  M papaverine as 100% relaxation. A graph was plotted by taking the percentage relaxation vs the log (M) concentration of the compounds. The relaxant activity of the test compound was assessed by calculating the mean relative potencies (MRP) and the mean activity ratio (MAR), both before and after tolerance, as defined below:

$$\text{MRP} = \frac{\text{Concentration of GTN producing 50\% of its maximum relaxation}}{\text{Concentration of test compound producing 50\% of the maximum relaxation of GTN.}}$$

10

$$\text{MAR} = \frac{\text{Maximum relaxation produced by the test compound}}{\text{Maximum relaxation produced by GTN}}$$

- 15 Selection criteria for in vivo study: Compounds having MRP greater than 3 and MAR greater than 1.3 after tolerance were selected for in vivo study. Dose response curve for compound 8 is given in Figs. 1 and 2 of the accompanying drawings as an example for the estimation of MRP and MAR.

**b) In vivo Pharmacological Screening:**

- 20 A modified method of Benedini et al (1995) was adopted for studying the anti-anginal effect of the chosen compounds. Guinea pigs of either sex, weighing approximately 400-600 g were used for this study. Animals were anesthetized with urethane (1.25 g/kg, i.p.) and jugular vein was cannulated for intravenous administration of drugs/vehicle. Mean arterial blood pressure (MABP) was monitored

by a cannula inserted into the right carotid artery and connected to a pressure transducer. Standard limb lead II electrocardiogram was recorded continuously. All the recordings were carried out on a MacLab system (AD Instruments, UK).

The ability of the test compounds to suppress the vasopressin induced T-wave elevation was used as the model for studying the anti-anginal effects of the compounds. Guinea pigs were divided into two groups for the purpose of this study, i) control group (pretreated with the vehicle for the compound) and ii) drug treated group.

**i) Control Group**

In this group of animals the solvent used for dissolving the test compound was administered intravenously in a volume of 1 ml/kg. The basal T-wave heights, heart rates and MABP and changes after vehicle administration were noted. Thirty seconds later 1 I.U./ ml/kg of vasopressin was administered intravenously. The T-wave heights, heart rates and MABP and their changes after vasopressin administration were also noted. The T-wave elevation (after vasopressin administration), maximum rise in MABP, and changes in heart rate were calculated from the above data and expressed as mean  $\pm$  standard deviation.

**ii) Drug treated group**

The effects of the test compound in suppressing the T-wave elevation caused by vasopressin were evaluated with atleast three dose levels. Groups of 6 guinea pigs were used for each dose. The test compound was injected 30 seconds prior to vasopressin administration. Changes in MABP, heart rate and T-waves were recorded as described for the control group. The percentage inhibition of vasopressin induced T-wave elevation was calculated for each dose taking the T-wave height estimated in

control group as 100%. From the dose vs percent inhibition relationship, the dose required for 50% inhibition (ED<sub>50</sub>) for the T-wave elevation was estimated.

**Determination of the ED<sub>20</sub> values for drop in MABP**

In a separate group of animals the drop in MABP after administration of the test compound (dose range of 0.1 - 1000 µg/kg, i.v.) was studied. Atleast three animals were used for each dose. Care was taken so that the doses were given only after the MABP had stabilized from the effects of the previous dose. All doses were injected in a final volume of 1 ml/kg. The drop in MABP was noted for increasing concentrations of the test compound and a dose response curve was drawn. From this graph the dose required to produce a 20% fall in MABP (ED<sub>20</sub>) was calculated.

The specificity of the test compound was defined by the selectivity index, which was calculated as shown below:

$$\text{Selectivity Index} = \frac{\text{Dose required for 20\% reduction in MABP } (\mu\text{g/kg})}{\text{Dose required for 50\% inhibition of T-wave elevation } (\mu\text{g/kg})}$$

Compounds having selectivity ratio greater than 30 times that of GTN were selected for initial toxicology evaluation. The selectivity index for GTN was estimated to be 0.017.

**Results of in vitro Screening of NO Donors:**

The results of in vitro screening of the NO donors are given in the following Table 2.

**TABLE 2 - In vitro activity of NO donors**

| Compound No. | Mean Relative Potency before tolerance | Mean Relative Potency after tolerance | Mean Activity Ratio before tolerance | Mean Activity Ratio after tolerance |
|--------------|--|---------------------------------------|--------------------------------------|-------------------------------------|
| 1.           | 0.03                                   | 1.2                                   | 0.7                                  | 1.3                                 |
| 2.           | 1.7                                    | 2.9                                   | 1.0                                  | 1.3                                 |
| 3.           | Low Potency                            | Low Potency                           | 0.5                                  | 0.2                                 |
| 4.           | Low Potency                            | Low Potency                           | 1.3                                  | 1.2                                 |
| 5.           | Low Potency                            | Low Potency                           | 0.7                                  | 0.4                                 |
| 6.           | 0.8                                    | 3.4                                   | 1.3                                  | 1.5                                 |
| 7.           | 0.17                                   | 0.54                                  | 1.05                                 | 1.5                                 |
| 8.           | 0.18                                   | 7.99                                  | 1.44                                 | 1.36                                |
| 9.           | Low Potency                            | Low Potency                           | 0.32                                 | 0.52                                |
| 10.          | 0.08                                   | 1.6                                   | 1.2                                  | 1.25                                |
| 11.          | 0.79                                   | 16.36                                 | 1.17                                 | 1.72                                |
| 12.          | 0.44                                   | 9.0                                   | 1.06                                 | 1.6                                 |
| 13.          | 0.4                                    | 10.6                                  | 1.1                                  | 1.6                                 |
| 14.          | 0.71                                   | 11.5                                  | 1.1                                  | 1.25                                |
| 15.          | 0.028                                  | 2.73                                  | 0.92                                 | 0.88                                |
| 16.          | 0.06                                   | 0.46                                  | 1.07                                 | 0.92                                |
| 17.          | 0.017                                  | 0.85                                  | 0.75                                 | 0.85                                |
| 18.          | 0.046                                  | 3.79                                  | 0.82                                 | 1.43                                |
| 19.          | 0.06                                   | 9.28                                  | 1.03                                 | 2.07                                |

**Results of in vivo evaluation:**

The compounds, which were selected based on in-vitro studies, were subjected to in-vivo studies to assess their anti-anginal action. Compounds with sufficient selectivity (i.e. lower hypotension) and anti-anginal action are listed in Table - 3.

**TABLE 3 - In vivo activity of selected Nitric Oxide donors**

| Compound No. | Dose required for 20% fall in B.P. (ED <sub>20</sub> µg/kg.) (A) | Dose required for 50% inhibition of T-wave (ED <sub>50</sub> µg/kg.) (B) | Selectivity Index (A/B) (C) |
|--------------|--|--|-----------------------------|
| GTN          | 8.22   | 474.40   | 0.017                       |
| 6            | 383.19   | 170.70   | 2.25                        |
| 8            | 539.06   | 93.75  | 5.75                        |
| 12           | 248.86   | 681.68   | 0.37                        |
| 13           | 318.55   | 113.16   | 2.81                        |



It was observed that compounds 6, 8, 12 and 13 have a high selectivity index as compared to GTN. In the case of compounds 6, 8 and 13, the index is significantly higher. The index showed that these compounds could elicit anti-anginal activity at a dose, which had minimum systemic effects. Their selectivity in dilating the coronary  
5 arteries was quite high as compared to a conventional drug like GTN.

The high selectivity index of these compounds as compared to nitroglycerine show that they selectively dilate the coronary arteries and have a lower tendency to cause hypotension during clinical usage. For example, the compound with lowest selectivity index, (compound 12), is 22 times more selective as compared to GTN. This shows  
10 that these compounds have very little tendency to cause hypotension. Conventional nitrates like GTN cause tachycardia, retrosternal discomfort, palpitations, collapse, syncope and postural hypotension, etc. as a manifestation of hypotensive effect. This could limit its use in selected patients. However, the compounds described in this invention due to a lower tendency to cause hypotension are superior to conventional  
15 nitrates.

The benzofuroxans described in this invention can be used in cardiovascular disorders like acute effort angina, angina prophylaxis, mixed angina and silent ischemia, acute myocardial infarction, congestive heart failure, etc. They can be used alone or in combination with beta adrenergic blockers like propranolol, atenolol,  
20 carvedilol, etc. and calcium channel antagonists like verapamil, diltiazem, etc.

The method of preparation of the representative compounds for use in treatment of cardiac disorders according to this invention are given in the following examples:

**EXAMPLE 1: Preparation of 5(6)- n-propylmercapto benzofuroxan. (Compound 2):**

In a 250 ml round bottom flask, was added 10.0 g of 2-nitro -4-thiopropylaniline. To it was added 50 ml of D.M. water and 40 ml concentrated HCl. It was stirred at 0-10°C for 1 hour. Then at 0°C, a solution of 4.7 g of sodium nitrite  
5 in 10 ml water was added. After 10 minutes 4.5 g of sodium azide in 10 ml water was added to obtain 6.2 g of 2- nitro -4- thiopropyl phenyl azide as a yellow solid.

12 ml of dry toluene, was charged with 2.0 g of 2- nitro -4- thiopropyl phenyl azide. The dark brown solution which was formed was stirred at 80°C for 4 hours. The solvent was removed under vacuum to give a brown solid, which was further  
10 charcoalyzed in ethanol:water (7:3) and filtered to give 800 mg of 5(6)-n-propyl mercapto benzofuroxan.

IR(KBr) : 3092, 2967, 1605, 1517, 1456, 1293, 1125, 1090  $\text{cm}^{-1}$

PMR ( $\text{CDCl}_3$ )  $\delta$ : 6.8-7.5 (3H,m), 3.0 (2H,t), 1.8 (2H,m), 1.1 (3H,t)

Mass: 210 ( $\text{M}^+$ ), 150 ( $\text{M}^+ - \text{N}_2\text{O}_2$ )

**15 EXAMPLE 2: Preparation of 5(6)- methylmercapto benzofuroxan. (Compound 4):**

To a stirred mixture of 2 g of 4- thiocyanato -2- nitroaniline in 20 ml methanol was added a solution of 1.2 g potassium hydroxide in 10 ml methanol. The solution became dark. The mixture was stirred at 20°C for 2 hours. Then 1 g of methyl iodide was added when a clear solution was obtained in 2 minutes and it was stirred at  
20 20°C for 1 hour. Methanol was removed on a rotary evaporator at 40°C. Then 50 ml of water was added to the residue and the product was extracted with ethyl acetate. The organic extracts were combined and dried over anhydrous  $\text{Na}_2\text{SO}_4$ . Ethyl acetate was removed on a rotary evaporator when 1.2 g of 4- methylmercapto -2-

nitroaniline was obtained, which was used for the next step without further purification.

To a stirred mixture of 0.75 g 4-methylmercapto -2- nitroaniline and 5 ml concentrated HCl was added 20 ml of water, and stirring was continued for another 5 minutes. The mixture was cooled to 0°C and then a solution of 1 g of sodium nitrite in 5 ml water was added and stirred at 0°C for 2 hours. It was then filtered rapidly under suction and the filtrate was collected. To the filtrate was added a solution of 1.5 g of sodium azide in 5 ml water when a solid was precipitated with frothing. The solid was extracted with methylene chloride (50 ml x 2). The combined organic  
10 extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated on a rotary evaporator when 0.5 g of 4- methylmercapto -2- nitrophenyl azide was obtained. The solid was used for the next step without further purification.

A mixture of 0.5 g 4- methylmercapto -2- nitrophenyl azide and 10 ml toluene was heated with stirring at 100°C for 2 hours. Toluene was removed under vacuum at  
15 60°C and recrystallization was carried out with hexane:ethylacetate (5:7) when 0.41 g of 5(6)- methylmercapto benzofuroxan was obtained.

m.p.: 114°C

IR (KBr): 2920, 1600, 1515, 1460 cm<sup>-1</sup>

**EXAMPLE 3:** Preparation of 5(6)- n-propoxy carbonyl benzofuroxan.

20 (Compound 12):

5(6)- Carboxy benzofuroxan (2.0g, 0.11 mole) was refluxed in a saturated solution of n- propionic HCl for 16 hours. n-Propanol was removed under vacuum and the residue was redissolved in diethyl ether (150 ml). The solution was then washed with aqueous NaOH (50ml, 0.1mole), followed by water (100 ml) and dried over Na<sub>2</sub>SO<sub>4</sub>

Ether was removed under vacuum to give an oil which was purified by column chromatography.

Yield: 1.0g, (45%)

m.p.: 30-32°C

5 IR (KBr): 1725, 1613, 1585, 1540, 1490  $\text{cm}^{-1}$

P.M.R. (200 MHz,  $\text{CDCl}_3$ ) $\delta$ : 1.09-1.08 (2H,t,J=7.4Hz), 1.58-2.17(2H,m), 4.30-4.36 (3H,t,J=6.6Hz), 7.36-7.86 (3H,m).

Mass: 222( $\text{M}^+$ ), 180, 163, 75.

Alternatively, compound 12 can also be prepared by the following procedure:

10 5(6)-Chlorocarbonyl benzofuroxan (100 mg) and n-propyl alcohol (150 mg) were dissolved in THF (10ml) at room temperature. To the reaction mixture triethylamine (0.1 ml) was added and reaction mixture was refluxed for 24 hrs. THF was removed under reduced pressure. To the residue 10 ml water was added and extracted with ethyl acetate (3 x 20 ml). Ethyl acetate was removed under reduced  
15 pressure to get sticky mass which was purified by column chromatography using ethylacetate: hexane (1:9) to give 65 mg of compound 12.

Compound 12 can also be prepared by the method of preparation of compound 13.

**EXAMPLE 4:** Preparation of 5(6)- isopropoxy carbonyl benzofuroxan. (Compound  
20 13):

To a solution of 5(6)- carboxy benzofuroxan (1.0g, 0.0055 mole) and isopropyl alcohol (0.9 ml., 0.01 mole) in  $\text{CH}_2\text{Cl}_2$  (50 ml) were added 4- dimethylamino pyridine (70 mg) and N,N'- dicyclohexyl carbodiimide (2.28g, 0.011 mole) under stirring. The reaction mixture was stirred for 2 hours at room temperature. It was

filtered and the filtrate on evaporation under reduced pressure gave crude product, which was purified by column chromatography (n- hexane) to give the title compound as yellow solid (0.7 g, 57%).

m.p.: 65-67°C

5 IR (KBr): 1716, 1622, 1585, 1537  $\text{cm}^{-1}$

PMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ : 1.3-1.41 (6H,d,J=6.2Hz), 5.15-5.37 (1H,m), 7.51-8.21 (3H,m),

Mass: 222 ( $M^+$ ), 180, 163, 103, 75.

Compound 13 can also be prepared by the method of preparation of compound 12.

#### 10 Oral Formulations:

Orally they may be administered as solid dosage forms for example as pellets, granules, powder, sachet or as discrete units such as tablets or capsules, etc.. Other orally administered pharmaceutical preparations include monophasic and biphasic liquid dosage forms either in ready to use form, or forms suitable for reconstitution  
15 such as mixtures, syrups, suspensions or emulsions. The preparations in addition may contain diluents, dispersing agents, buffers, stabilizers, solubilizers, surface active agents, preservatives, chelating agents and/or other pharmaceutical additives. Aqueous or non aqueous vehicles or their combination may be used and if desired may contain suitable sweeteners, flavouring agents or similar substances. In the case of a  
20 suspension or emulsion a suitable thickening agent, suspending agent or emulsifying agent may be present. Pharmaceutical preparations can have a slow, delayed or controlled release of active ingredients as is provided by a matrix or diffusion controlled system.

**Parenteral formulations:**

For parenteral administration, the compounds or their salts or suitable complexes may be presented in a sterile vehicle which may be an aqueous or non aqueous vehicle or a combination thereof. The examples of vehicles are water, ethyl oleate, oils and derivatives of polyols, glycols and their derivatives. It may contain additives common in injectable preparations like stabilizers, solubilizers, pH modifiers, buffers, antioxidants, cosolvents, complexing agents, tonicity modifiers, etc. Some suitable additives are for example tartrate, citrate, or similar buffers, alcohols, sodium chloride, dextrose and high molecular weight liquid polymers. Another alternative is sterile powder for reconstitution. The compound may be administered in the form of injection, intravenous infusion/drip, or suitable depot preparation.

When the present invention, its salts or a suitable complex is presented as a discrete unit dosage form like a tablet, it may contain in addition medically inert excipients as are used in art. Diluents such as starch, lactose dicalcium phosphate, lubricants or similar additives like talc, magnesium stearate, polymeric substances like methyl cellulose, hydroxy propyl cellulose, fatty acids and derivatives, sodium starch glycollate, etc. can also be used.

**EXAMPLE 5:** Preparation of oral dosage form of the benzofuroxan derivatives given in Table 1.

The compounds described in Table 1 can be prepared in the form of tablets, containing the active ingredient in the range of 0.03 to 3 mg per tablet. A typical tablet has the following composition:

|                   |                |
|-------------------|----------------|
| Active ingredient | as given above |
| Starch            | 27 mg          |

|                              |        |
|------------------------------|--------|
| Lactose                      | 70 mg  |
| Polyvinyl pyrrolidone (k-30) | 1.0 mg |
| Talc                         | 1.5 mg |
| Magnesium stearate           | 0.5 mg |

- 5 **EXAMPLE 6:** Preparation of parenteral dosage form of benzofuroxan derivatives  
given in Table 1:

A preparation suitable for parenteral administration has the following composition:

|                            |        |
|----------------------------|--------|
| Active ingredient          | 1 mg.  |
| Poly ethylene glycol - 400 | 0.5 ml |

- 10 Isotonic saline solution q.s.

or water for injection 1 ml


These examples are presented by way of illustration alone and in no way limit the  
scope of the invention.

15

20

**I CLAIM:**

1. The use of a compound of the benzofuroxan series represented by the general formula (I)



5 and pharmaceutically acceptable salts thereof wherein:

R is halogen, acetoxy, -X-R', -C(O)NR''R''', or -C(O)Cl

10 wherein X is oxygen, sulfur, -C(O)-, or -C(O)O-

R' is hydrogen, straight chain or branched lower alkyl (C<sub>1</sub> - C<sub>8</sub>);

15 R'' and R''' is independently hydrogen, straight chain or branched lower alkyl (C<sub>1</sub> - C<sub>8</sub>)

or R'' and R''' are linked together with or without heteroatom such as oxygen or nitrogen wherein substitution on nitrogen is hydrogen or lower alkyl, in cardiovascular

20 disorders like coronary heart diseases.

2. The use of a compound of general formula (I) as claimed in claim 1, wherein the substituent R is in 5(6) position.

25 3. The use of a compound as claimed in claim 1 or 2, as a tolerance resistant antianginal compound.

30 4. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-isopropoxycarbonyl benzofuroxan.

35 5. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-n-propoxycarbonyl benzofuroxan.



6. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-methoxycarbonyl benzofuroxan.
- 5 7. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-chlorocarbonyl benzofuroxan.
8. The use of a compound as claimed in claim 3, wherein said tolerance resistant  
10 antianginal compound is 5(6)-tertiarybutyl amino carbonyl benzofuroxan.
9. The use of a compound as claimed in claim 3, wherein said tolerance resistant  
15 antianginal compound is 5(6)- ethoxy carbonyl benzofuroxan.
10. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)- formyl benzofuroxan.
- 20 11. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-isopropylamino carbonyl benzofuroxan.
- 25 12. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)- n-propylmercapto benzofuroxan.
13. The use of a compound as claimed in claim 3, wherein said tolerance resistant  
30 antianginal compound is 5(6)- chloro benzofuroxan.
14. The use of a compound as claimed in claim 3, wherein said tolerance resistant  
35 antianginal compound is 5(6)-tertiary butoxy carbonyl benzofuroxan.
15. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)- amino carbonyl benzofuroxan.
- 40 16. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-morpholino carbonyl benzofuroxan.
- 45 17. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)-dimethylamino carbonyl benzofuroxan.

18. The use of a compound as claimed in claim 3, wherein said tolerance resistant antianginal compound is 5(6)- [(4-methyl) piperazine -1- yl] carbonyl benzofuroxan.
- 5 19. A pharmaceutical composition of the compounds of general formula (I) as claimed in claim 1, wherein the said composition contains pharmaceutically active amount of a compound of general formula (I) and a pharmaceutically acceptable  
10 carrier.
20. The pharmaceutical composition as claimed in claim 19, in the form of an oral  
15 formulation.
21. The pharmaceutical composition as claimed in claim 19, wherein said pharmaceutically acceptable carrier is selected from one or more of the compounds  
20 like starch, lactose, polyvinyl pyrrolidone (k-30), talc and magnesium stearate.
22. The pharmaceutical composition as claimed in claim 19, in the form of a  
25 parenteral formulation.
23. The process for the preparation of a parenteral formulation, as claimed in claim 22, which comprises dissolution of the active ingredient of general formula (I) in  
30 polyethylene glycol 400 and diluting the solution so obtained, with an isotonic solution or water to the desired concentration.
- 35 24. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-isopropoxycarbonyl benzofuroxan.
25. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
40 the active compound of formula (I) is, 5(6)-n- propoxycarbonyl benzofuroxan.
26. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
45 the active compound of formula (I) is, 5(6)-methoxycarbonyl benzofuroxan.
27. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein

the active compound of formula (I) is, 5(6)-chlorocarbonyl benzofuroxan.

28. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein

5 the active compound of formula (I) is, 5(6)-tertiarybutyl amino carbonyl benzofuroxan.

10 29. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-ethoxycarbonyl benzofuroxan.

30. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
15 the active compound of formula (I) is, 5(6)-formyl benzofuroxan.

31. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
20 the active compound of formula (I) is, 5(6)-isopropylamino carbonyl benzofuroxan.

32. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
the active compound of formula (I) is, 5(6)-n- propylmercapto benzofuroxan.

25 33. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-chloro benzofuroxan.

30 34. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-tertiarybutoxy carbonyl benzofuroxan.

35 35. A pharmaceutical composition as claimed in claims 19, 20, 21, 22, or 23, wherein the active compound of formula (I) is, 5(6)-aminocarbonyl benzofuroxan.

36. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
40 the active compound of formula (I) is, 5(6)-methylmercapto benzofuroxan.

37. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein  
the active compound of formula (I) is, 5(6)-morpholino carbonyl benzofuroxan.

45 38. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-dimethylamino carbonyl benzofuroxan.

39. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-[(4-methyl) piperazine -1- yl] carbonyl

5 benzofuroxan.

40. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-hydroxy benzofuroxan hydrochloride.

10

41. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-acetoxy benzofuroxan.

15

42. A pharmaceutical composition as claimed in claims 19, 20, 21, or 22, wherein the active compound of formula (I) is, 5(6)-carboxy benzofuroxan.

20

43. A method for the treatment of mammal including man, of coronary heart diseases comprising administration of an effective amount of a compound of general formula (I) as defined herein.


25

30

35

40

45






Fig - 2

PCT/IB 99/00893

IPC 6 A61K31/41 //C07D271/12

IPC 6 A61K

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## Relevant to claim No.

1-43

X EP 0 574 726 A (CASSELLA  
AKTIENGESSELLSCHAFT)  
22 December 1993 (1993-12-22)  
the whole document

1-43

- / - -

☒ Patent family members are listed in annex.

"&" document member of the same patent family

06/09/1999

Allard, M

**BEST AVAILABLE COPY**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/00893

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.               |
|------------|---|-------------------------------------|
| X          | GHOSH P B ET AL: "Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological activity of some benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans)"<br>JOURNAL OF MEDICINAL CHEMISTRY,<br>vol. 11, no. 2, 1968, pages 305-11,<br>XP002113125<br>page 307, table I, entries 25, 26, 28-30,<br>32, 35-38<br>--- | 19,26,<br>29,30,<br>33,35,<br>41,42 |
| X          | EP 0 431 944 A (MERCK & CO. INC.)<br>12 June 1991 (1991-06-12)<br>claims 1-8<br>---   | 19                                  |
| X          | CHEMICAL ABSTRACTS, vol. 125, no. 1,<br>1 July 1996 (1996-07-01)<br>Columbus, Ohio, US;<br>abstract no. 10756q,<br>ZHANG W ET AL: "Synthesis and<br>hypoxia-selective cytotoxicity of<br>benzofuraxans and quinoline di-N-oxides"<br>page 1182;<br>XP002113146<br>abstract<br>& ZHONGGUO YAOWU HUAXUE ZAZHI,<br>vol. 5, no. 4, 1995, pages 242-4, 270,<br>---         | 19                                  |
| P,X        | WO 98 35950 A (COTEX PHARMACEUTICALS,<br>INC.) 20 August 1998 (1998-08-20)<br>the whole document, particularly<br>example 3<br>-----  | 19                                  |



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 99/00893

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-18 and 43  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-18 and 43  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/00893

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| EP 574726 A                               | 22-12-1993          | DE 4218977 A               | 16-12-1993          |
|   |                     | CA 2098058 A               | 11-12-1993          |
|   |                     | HU 66084 A                 | 28-09-1994          |
|   |                     | JP 6087863 A               | 29-03-1994          |
|   |                     | US 5360812 A               | 01-11-1994          |
|   |                     | ZA 9304024 A               | 06-01-1994          |
| EP 431944 A                               | 12-06-1991          | US 5032604 A               | 16-07-1991          |
|   |                     | CA 2031645 A               | 09-06-1991          |
|   |                     | JP 3209372 A               | 12-09-1991          |
|   |                     | US 5112824 A               | 12-05-1992          |
| WO 9835950 A                              | 20-08-1998          | AU 6159998 A               | 08-09-1998          |
|   |                     | GB 2325225 A, B            | 18-11-1998          |